Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
30
NCT06075849
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 25, 2023
Completion: Jan 31, 2025